Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

French National Agency for Research on AIDS and Viral Hepatitis

Status and phase

Terminated

Phase 3

Conditions

Hepatitis C, Chronic

Treatments

Drug: ribavirin

Drug: amantadine

Drug: peg-interferon alfa-2b

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00122629

ANRSHC03 BITRI

Details and patient eligibility

About

Triple antiviral therapy with peg-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination.

Patients with hepatitis C virus infection were eligible if they had failed to respond to a single previous 24 week cycle of interferon/ribavirin combination therapy. Non-response was defined as persistent HCV RNA in the serum during the last month of treatment.

This study tested the efficacy and safety of pegylated interferon alfa-2b with ribavirin and amantadine or a placebo for 48 weeks.

Full description

Triple antiviral therapy with peg-interferon-alfa/ribavirin + amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination.

The aim of this study is to determine if the addition of amantadine to PEG-IFN/ribavirin enhances SVR.

This study is a double blind, comparative, prospective multicenter, randomized study. Patients are recruited from 23 hepatology centers in France. The protocol was approved by the French ethical committee and all patients provided written informed consent. Eligible subjects are randomly assigned to the two treatment groups in equal proportions. The randomization process is generated by the Department of Biostatistics, Hospices Civils de Lyon, Lyon, France.

Main inclusion criteria are: elevated ALT, detectable HCV RNA, Metavir score over or equal to A1F1 and below or equal to F3. Patients received PEG-IFN 1.5µg/kg/week, ribavirin 800-1200mg/day and amantadine 200mg/day or placebo during 48 weeks.

The primary endpoint is a sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation (week 72). Secondary endpoints are the biochemical response at week 72 defined as ALT normalization; histological benefit; tolerance; and virological and biochemical responses during therapy at weeks 12, 24 and 48.

Sex

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Positive anti-HCV antibody test
Patients who did not respond to treatment with standard interferon + ribavirin (HCV RNA+ by PCR in the last month of treatment)
Compensated liver disease
Neutrophil count over or equal to1000/mm3
Platelet count over or equal to 100 giga/L
Haemoglobin over or equal to 10g/dL
Patients had to have undergone a post-treatment liver biopsy within a year, showing a METAVIR histological score over or equal to A1F1, without cirrhosis (fibrosis score below F4)
ALT over N and HCV RNA+ at screening

Exclusion criteria

Co-infection with hepatitis B or human immunodeficiency virus
Any other cause of liver disease
Active drug abuse, active alcohol consumption above 40g/day
Organ grafts
Presence of hepatocellular carcinoma
Cardiovascular, metabolic, renal, haematological, neurological or psychiatric disease
Patients with previous amantadine use
Systemic immunosuppressive or antiviral treatment during the last 24 weeks and those with a history of interferon and/or ribavirin intolerance